Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.43
23.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Selling, General & Administrative
Shijiazhuang Yiling Pharmaceutical Co Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
|
Selling, General & Administrative
-¥2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Selling, General & Administrative
-¥4.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Selling, General & Administrative
-¥1.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-14%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Selling, General & Administrative
-¥10.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Selling, General & Administrative
-¥6.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Selling, General & Administrative
-¥361.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
Glance View
Shijiazhuang Yiling Pharmaceutical Co Ltd, rooted in the northern heart of China, embodies a harmonious blend of traditional Chinese medicine and modern pharmaceutical science. Born from the insightful vision of Wu Yiling, a prominent figure in integrating traditional Chinese medical practices with contemporary research methodologies, the company has grown into a significant player in the healthcare sector. Its foundation is deeply entrenched in leveraging ancient herbal wisdom while adopting cutting-edge biopharmaceutical technologies. At the core of its operations, Yiling Pharmaceutical specializes in the research, development, and production of therapeutic drugs aimed at treating chronic diseases and boosting immunity. This dual approach allows the company to carve out a niche in producing signature products like Lianhua Qingwen, a respiratory treatment renowned for its efficacy in alleviating symptoms from colds and flu. What powers Yiling Pharmaceutical's continued growth is its steadfast commitment to research and development, translated into a structured pipeline of innovative drugs. The company's funding funnel directs substantial resources into ongoing research, ensuring a constant expansion and refinement of their product portfolio. With an emphasis on effectiveness backed by rigorous scientific validation, Yiling has successfully navigated the complexities of pharmaceutical regulations, extending its reach beyond domestic borders to international markets. This expansionist strategy, coupled with a deep understanding of traditional medicine, forms a robust revenue stream, encapsulating both the domestic market's demand for traditional therapies and the international community's growing interest in alternative medicine solutions. Through these channels, Yiling harmonizes its traditional roots with a forward-thinking business model, ensuring steady financial footholds and promising horizons.
See Also
What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-2.9B
CNY
Based on the financial report for Sep 30, 2024, Shijiazhuang Yiling Pharmaceutical Co Ltd's Selling, General & Administrative amounts to -2.9B CNY.
What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-7%
Over the last year, the Selling, General & Administrative growth was 26%. The average annual Selling, General & Administrative growth rates for Shijiazhuang Yiling Pharmaceutical Co Ltd have been 12% over the past three years , -4% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
